Gene: PLEKHA8
Official Full Name: pleckstrin homology domain containing A8provided by HGNC
Gene Summary: Enables several functions, including ceramide binding activity; glycolipid transfer activity; and phosphatidylinositol-4-phosphate binding activity. Involved in ER to Golgi ceramide transport. Located in nucleoplasm and trans-Golgi network. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO24676 | PLEKHA8 Knockout cell line (HeLa) | Human | PLEKHA8 | 1:3~1:6 | Negative | Online Inquiry |
KO24677 | PLEKHA8 Knockout cell line (HCT 116) | Human | PLEKHA8 | 1:2~1:4 | Negative | Online Inquiry |
KO24678 | PLEKHA8 Knockout cell line (HEK293) | Human | PLEKHA8 | 1:3~1:6 | Negative | Online Inquiry |
KO24679 | PLEKHA8 Knockout cell line (A549) | Human | PLEKHA8 | 1:3~1:4 | Negative | Online Inquiry |
PLEKHA8 Gene Knockout Cell Lines are specifically engineered cellular models designed to enable profound insights into the biological functions and pathways regulated by the PLEKHA8 gene. This gene has been implicated in various critical cellular processes, including cellular signaling, endocytosis, and organelle dynamics. Utilizing CRISPR/Cas9 technology, our knockout cell lines provide a robust tool for dissecting the roles of PLEKHA8 in various physiological and pathological contexts, thereby facilitating the examination of its influence on cancer progression, metabolic disorders, and neurodegenerative diseases.
The PLEKHA8 knockout mechanism operates by introducing precise mutations into the gene sequence, leading to the loss of function. This targeted modification allows researchers to study the consequences of PLEKHA8 deficiency on cellular behavior and gene expression. In research settings, these cell lines can be pivotal for elucidating underlying mechanisms of disease, testing therapeutic interventions, and screening for novel compounds that may modulate PLEKHA8-related pathways.
Distinctively, our PLEKHA8 Gene Knockout Cell Lines offer several advantages over conventional knockout strategies. They are fully validated for consistent performance, ensuring reproducibility and reliability of results. Furthermore, the specificity of CRISPR technology minimizes off-target effects, an often-overlooked aspect that can significantly skew experimental outcomes. Consequently, researchers can generate more accurate data while expediting the discovery of therapeutic targets.
For clinicians and researchers alike, the valuation of our PLEKHA8 Gene Knockout Cell Lines lies in their potential to advance functional genomics and accelerate drug development processes. By providing a clearer understanding of PLEKHA8’s role in disease, these models are instrumental in devising targeted therapeutic strategies, ultimately contributing to improved patient outcomes.
With a commitment to innovation and scientific excellence, our company leverages years of expertise in genetic engineering and cell biology, offering high-quality biological products that empower researchers to push the boundaries of their investigative pursuits.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.